Kexing Biopharm Deepens Its Presence in the Greater Bay Area Pharmaceutical Market as Three Partnered Products Receive Marketing Approval in Macao, China

Article source：Aug 26,2026View： 257

Recently, three products in-licensed by Kexing Biopharm—Aflibercept Intraocular Injection, Nintedanib Esylate Soft Capsules, and Lacosamide Tablets—officially received registration approval from the Pharmaceutical Supervision and Administration Bureau of the Macao Special Administrative Region Government (ISAF). The three products cover three major therapeutic areas: ophthalmology, pulmonary diseases, and neurology. The continued approval and launch of multiple products once again demonstrate the strength of Kexing Biopharm’s commercialization platform.

Aflibercept Intraocular Injection is a humanized fusion protein that binds to vascular endothelial growth factors (VEGF-A and VEGF-B) and placental growth factor (PlGF). It is primarily indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) in adults. According to data from Pharmcube, the original aflibercept product generated global sales of US$9.554 billion in 2024, ranking first among ophthalmic drugs by sales. In 2025, Kexing Biopharm and Boan Biotech entered into an overseas commercialization partnership for the aflibercept biosimilar in designated regions.

The Nintedanib Esylate Soft Capsules jointly commercialized overseas with Humanwell PuraCap pharmaceutical (Wuhan) are among the therapies recommended by global clinical guidelines for the treatment of idiopathic pulmonary fibrosis (IPF). Its major indications include IPF, chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, and slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The product addresses significant unmet clinical needs. In 2025, global sales of the original nintedanib product reached €3.8 billion, representing year-on-year growth of approximately 5.4%.

Lacosamide Tablets are a third-generation broad-spectrum antiepileptic drug. They exert their antiepileptic effects by selectively enhancing the slow inactivation of voltage-gated sodium channels. According to a report by Research and Markets, the global lacosamide drug market is projected to reach US$2.35 billion by 2032, with a compound annual growth rate (CAGR) of approximately 9.09%. In addition, oral tablets account for the dominant share of both the oral and overall market due to their favorable patient compliance and convenience for long-term maintenance treatment at home. Lacosamide Tablets are the third drug jointly commercialized overseas by Kexing Biopharm and Qingfeng Kerui, with Macao, China, as the designated cooperation region.

To date, Kexing Biopharm has established a commercialization network covering approximately 70 countries and regions and has obtained overseas commercialization rights for more than 30 products. Its business spans multiple therapeutic areas, including oncology, autoimmune diseases, metabolic disorders, ophthalmology, and neurology.

Going forward, Kexing Biopharm will continue to deepen its presence in the Guangdong-Hong Kong-Macao Greater Bay Area pharmaceutical market, accelerate the registration and commercialization of more high-quality products, and provide patients with a broader range of treatment options.